Toronto, Ontario – The Newswire – August 2, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is thrilled to announce that it will be attending the 8th World Congress of Paediatric Cardiology and Cardiac Surgery in Washington, DC. This is the first time the congress will be held in the continental United States.  The conference will run from August 27th, 2023 – September 1st, 2023, in Washington DC.

“We are looking forward to this great event to showcase our AI empowered technology and products in the treatment and monitoring of congenital heart conditions and disease. We continue to build awareness of our products through these types of engagements; they are key to getting our product in front of clinicians so that they can see the power of the VMS+ products in elevating the cardiac care that they provide to their patients”, said Dr. Alvira Macanovic, President and CEO of Ventripoint Diagnostics.

The World Congress is typically held every four years and brings together over 4,500 participants comprised of international leaders in paediatric cardiology, cardiac surgery, cardiac intensive care, and other topics. The conference will be focused on congenital heart disease, echocardiography, pulmonary hypertension, big data, new technology and artificial intelligence.

The scientific program is interdisciplinary and has been developed by leaders in all disciplines of paediatric cardiac care. A program of unparalleled breadth and depth features 22 subspecialty tracks designed so professionals from all disciplines can customize their learning experience, based on their own needs. 

More than 1,500 scientific posters will showcase the latest science.  An interactive Multi-dimensional Anatomy Lab will showcase the evolution of cardiac imaging and a Digital Transformation Hub will showcase advanced technology that can be integrated into cardiovascular practice to drive innovative care. As an attendee of this prestigious event, Ventripoint will have the opportunity to engage with professionals in the paediatric cardiology field, as well as our distributors to continue to build our global network.  

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

For further information, please contact:

Jonathan Robinson CFA

This email address is being protected from spambots. You need JavaScript enabled to view it.

(416) 669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.